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Stents were initially used to manage or prevent acute vessel
closure after percutaneous transluminal coronary angioplasty
(PTCA). The first direct randomized comparison with
respect to restenosis showed the superiority of stenting to
PTCA for de novo lesions situated in native vessels 3 mm or
larger (1,2). In these trials, stenting was associated with a
25% to 30% reduction of restenosis as compared to PTCA
(1,2). This represented the first of a series of battles won by
stenting regarding restenosis. Trials that followed showed
better results after stenting than after PTCA for bypass graft
lesions (3), lesions situated in the proximal left anterior
descending coronary artery (4), restenotic lesions (5),
chronic occlusions (6) and in patients with acute myocardial
infarction (7). Accordingly, stent placement was unani-
mously indicated for the treatment of de novo or restenotic
lesions situated in large vessels (3 mm in size).
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Smaller vessels constitute a large group in daily practice of
percutaneous coronary interventions. Interventions in small
coronary vessels (2.8 to 3.0 mm) account for a consider-
able proportion (30% to 50%) of the 1 million coronary
catheter-based procedures performed worldwide each year
(8). Previous studies on balloon angioplasty without stent
placement have identified small vessel size as an indepen-
dent risk factor for the development of restenosis (8). After
the introduction of coronary stents, several retrospective
analyses have compared long-term results in small versus
large vessels, indicating that restenosis rates differ signifi-
cantly with vessel size. Elezi et al. (9) found that restenosis
rate increased from 20.4% in vessels 3.2 mm to 28.4% in
vessels 2.8 to 3.2 mm, and to 38.6% in vessels 2.8 mm.
Similar findings were described by Akiyama et al. (10), with
a rate of 19.9% in vessels 3 mm, and 32.6% in vessels
3 mm. Both studies have clearly indicated the mechanism
of this negative effect: the absolute late lumen loss after six
months in small vessels is equal to, or even higher, than in
larger vessels and, as the initial acute gain in smaller vessels
is significantly lower, net lumen gain decreases even more
dramatically, leading to a significantly higher restenosis rate.
On the basis of the available evidence, small vessel size
represents an important risk factor for an adverse outcome
both after PTCA and stenting. Post hoc quantitative
angiographic analyses of two randomized trials actually
designed for large vessels have suggested that stenting might
be a better option than PTCA for lesions in small coronary
vessels (11,12). However, because the data of these post hoc
analyses were not generated by specifically designed ran-
domized studies comparing stenting with PTCA, small
vessel size has not been considered an established indication
for stenting. As a result of the growing interest in this topic
in the last few years, more than half a dozen studies have
been dedicated to the randomized comparison between
stenting and PTCA for small coronary vessels, including
about 2,000 patients.
Heparin-coated beStent versus PTCA for small vessels.
The Stenting In Small Coronary Arteries (SISCA) study
published in this issue of the Journal (13) reports on the
results of one of the randomized trials comparing stenting
with PTCA for lesions in small coronary arteries. De novo
lesions situated in coronary vessels with a reference diameter
of 2.1 to 3.0 mm and with a length that could be covered
with a single 15-mm stent were included. For the compar-
ison with PTCA, the investigators (13) chose the heparin-
coated beStent. The primary end point of the trial was the
minimal lumen diameter (MLD) at follow-up angiography
after six months. On the basis of the sample size calculation
was the assumption that the primary end point after stenting
will be 0.2 mm greater than after PTCA. Accordingly, the
study intended to enroll 200 patients (13). The trial was
terminated by the sponsor after inclusion of 145 patients.
Abciximab was administered in 5% of the procedures; 14%
of the PTCA patients and 4% of the stent patients crossed
over to the opposite treatment approach. By six months,
only one patient had died and two patients had incurred
myocardial infarction (13). At follow-up, the primary end
point of the trial, MLD, was slightly better in the stent
group but without achieving statistical significance
(1.69 mm in the stent arm vs. 1.57 mm in the PTCA arm,
p  0.1).
A trend in favor of stenting was also seen regarding the
incidence of angiographic restenosis at six months: 9.7%
versus 18.8% in the PTCA group (p  0.15). Target lesion
revascularization due to restenosis was required in 8.1% of
the patients of the stent group and 16.9% of those in the
PTCA group between the first and sixth month (p  0.13).
Target vessel revascularization, a less sensitive index of
target lesion restenosis—considering the high proportion of
multilesion interventions in the study—was needed in 7.0%
of the PTCA patients and in none of the patients in the
stent arm. The only significant difference between the two
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groups was observed in the net lumen gain at six months,
with 0.72 mm for stent patients and 0.55 mm for PTCA
patients (p  0.02) (13). Summarizing these results, the
SISCA trial failed to achieve the target difference of 0.2 mm
in MLD in favor of stenting defined during study planning,
but showed a trend to less angiographic and clinical resten-
osis for stenting as compared to PTCA (13).
The SISCA trial has a number of strengths that deserve
comment. Although the stent type selected is the same as
that used in three other randomized trials dedicated to small
vessel intervention, the use of heparin coating is a distinct
characteristic of the SISCA trial. However, the extremely
low restenosis rate found after stenting despite the small
vessel size cannot be explained with the heparin coating of
the stents used in this trial. In a porcine model, heparin
coating indeed reduced stent thrombogenecity but was not
able to decrease neointimal hyperplasia (14). These experi-
mental results have recently been corroborated by a random-
ized clinical trial showing no influence on restenosis with
heparin coating (15).
Another advantage of the SISCA trial is the very high
reangiography rate at six months, with 141 of the 145 study
patients having undergone the angiographic follow-up. This
enables a highly reliable analysis of the primary end point.
Angiographic indexes are sensitive markers of restenosis and
carry a low risk of bias particularly when reangiography is
routinely done and quantitative assessment is performed in
an independent core laboratory. The alternative strategy of
clinically driven reangiography may not be appropriate
especially for patients who undergo interventions in small
vessels because restenosis-induced symptoms may be less
severe for small vessels as compared to larger vessels. In
addition, stent versus PTCA trials are by nature open-label
trials, and the inability to blind the operator as to the
approach utilized can influence the decision to reintervene
independently of the severity of angiographic restenosis and
lead to a potential bias when target vessel revascularization
serves as an isolated end point. Finally, Moer et al. (13) are
to be commended for the overall low restenosis rate, both in
the stent and in the PTCA group. These results are enviable
even for interventions in larger vessels. The procedural data
presented in their report (13) do not, however, provide
insights into the potential mechanisms responsible for this
excellent outcome.
Parallel to the strengths of the study of Moer et al. (13),
there are also relevant limitations that should be accounted
for before trying to draw conclusions. The only advantage
with the use of MLD as the primary end point is that it
allows for a smaller sample size in the trial. However, even
if the investigators had found a significant difference in
MLD between stent and PTCA alternatives, they would
not have been able to convince interventional cardiologists
about the superiority of stenting unless there was a signifi-
cant difference in conventional indexes of restenosis such as
the restenosis rate. Furthermore, both the protocol-
mandated number of patients and the number of patients
actually included are low. The premature termination of the
trial by the manufacturer of the study device had a partic-
ularly negative impact in this regard. Did the company
regret this act later, after the trend in favor of its product
was found? We do not know, but this fact underscores the
need for binding contracts between the investigators and
manufacturers of study drug/device prior to initiation of
patient enrollment.
Therefore, the SISCA trial alone is not able to solve the
conundrum, which concerns what is the best interventional
option for lesions in small coronary vessels due to the
limited size of the population included and to the less than
expected difference in the primary end point between the
two treatment arms. However, six other randomized trials
using four different stent types may help further in finding
an answer. Common findings of all these trials are that
stenting is associated with a significantly greater MLD at
the end of the procedure and that provisional stenting is
needed in about 20% of the patients initially assigned to
PTCA.
Other stents versus PTCA for small vessels. In the study
by Park et al. (16), 120 patients were randomly assigned to
either placement of NIR stents or balloon angioplasty. At
follow-up angiography, restenosis rates were 35.7% in the
stent group and 30.9% in the PTCA group (p  NS) (16).
In the ISAR-SMART (Intracoronary Stenting or Angio-
plasty for Restenosis Reduction in Small Arteries) trial (17),
404 patients were randomly assigned to placement of a
Multi-Link stent or PTCA. All patients received abciximab
periprocedurally, which differs from other trials that did not
give it systematically. At follow-up angiography, the resten-
osis rate was 35.7% among stent patients and 37.4% among
PTCA patients (pNS) (17). In the BESMART (BeStent
in Small Arteries) trial, a total of 381 patients were
randomized to either placement of a beStent or PTCA (18).
After six months, the restenosis rate was 21% after stenting
and 47% after PTCA (p  0.001) (18). The SISA study
(Stenting In Small Arteries) included 352 patients (19). The
stent used for this trial was also the beStent. After six
months, the restenosis rate was 28% after stenting and
32.4% after PTCA (p  NS) (19).
In the RAP study (Restenosis en Arterias Pequen˜as), 426
patients were randomized to receive either a beStent or
PTCA (20). At follow-up angiography, the restenosis rate
was 27% among stent and 37% among PTCA patients (p
0.05) (20). The CORDIS-MICA (MiniCrown stent In
small Coronary Arteries) trial was performed with the
MiniCrown stent (21). With 600 patients initially man-
dated by the protocol, the trial was stopped by the sponsor
after randomization of 128 patients. The trial had a very
high crossover rate of 37% in the PTCA arm. Based on a
very low number of repeat angiographies, mainly driven by
recurrent symptoms, restenosis rates were high but not
significantly different, with 61% after stenting and 63% after
PTCA (p  NS) (21).
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Which option should be used in small coronary arteries?
Figure 1 summarizes the restenosis findings of the random-
ized trials stent versus PTCA for lesions in small coronary
vessels. It is clearly evident that stenting of small vessels
leads to results equivalent to or better than those achieved
with PTCA. For the moment, it is difficult to explain the
differences among the various trials regarding the extent of
benefit with stenting. However, two factors deserve special
attention as a potential explanation for the different results.
First, the results suggest a role for the stent type used in
small coronary arteries as it has already been demonstrated
for larger vessels (22–24). The trials in which the beStent
was used (13,18–20) showed better results for the stent arm
than did the trials with stent types other than beStent
(16,17,21). Second, the benefit with stenting in terms of
restenosis reduction seems to be dependent on the final
result achieved with PTCA. As shown in Figure 2, a good
correlation existed between the residual stenosis after
PTCA and the difference in restenosis rate in favor of
stenting in the small vessel trials. This means that it is
certainly better to stent than to be satisfied with a subopti-
mal post-PTCA result.
In addition, as illustrated in Figure 2, the results of the
trials clearly show that the maximum that can be expected
after PTCA, even after achievement of an optimal result, is
a long-term outcome equivalent to that achieved with a
systematic stenting strategy. Thus, taken together, the
results of the randomized trials including the present study
of Moer et al. (13) do not discourage the routine use of
stenting for lesions in small coronary arteries; they only
show that a strategy based on optimal PTCA with provi-
sional stenting is probably as effective over the long term as
the alternative strategy of systematic stenting. Unless future
studies show a benefit for brachytherapy in small vessels, the
improvement potential of PTCA seems to be exhausted
with the achievement of an optimal acute result. In contrast,
coated and drug-eluting stents (25) represent promising
new technologies that could turn stents into highly attrac-
tive devices for treating lesions in small coronary arteries.
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